Peptide Library

Human study PLS-00152

F-Actin is associated with a worsening qSOFA score and intensive care unit admission in emergency department patients at risk for sepsis.

Prospective cohort · 203 participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • F-Actin is associated with a worsening qSOFA score and intensive care unit admission in emergency department patients at risk for sepsis.primary · Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2020-06-01 · PMID 32421363 · DOI

Design and participants

Design
Prospective cohort
Population
Adult emergency department patients (>18 years) meeting the Shock Precautions on Triage Sepsis rule, placing them at risk for sepsis.
Conditions
Sepsis, Septic shock
Setting
Emergency department
Planned enrollment (registry)
Not reported
Enrolled
203
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Higher plasma F-actin measured in the ED was associated with greater illness severity on qSOFA and with ICU admission, and may help risk-stratify suspected sepsis. Thymosin Beta 4 was not associated with or predictive of any significant outcome.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate population: Thymosin β4 was only measured as an endogenous plasma biomarker. It was never administered, so the study gives no information on its effects as a treatment.
    • abstract only: Only the PubMed abstract is available, so methods, analyses and funding details cannot be assessed.
    • other: Thymosin beta-4 was measured as an endogenous biomarker and not administered, so the study gives no information on treatment effects or safety.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 32421363, abstract (Conclusion, sentences 1-2; Results, sentence 3) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 32421363, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 32421363, abstract (Results, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 32421363, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).